Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Monopar Therapeutics Inc. has received a consensus rating of "Buy" from ten analysts, with an average 12-month price target of $86.22.
• Recent insider activity includes CEO Chandler Robinson selling 16,800 shares at an average price of $40.00, leading to an 18.61% decrease in his ownership stake.
• The company's stock opened at $81.67, with significant price fluctuations over the past year ranging from a low of $4.50 to a high of $81.89.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have received an average rating of "Buy" from the ten analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $86.2222.

MNPR has been the subject of several analyst reports. Lake Street Capital started coverage on shares of Monopar Therapeutics in a research note on Tuesday, September 23rd. They issued a "buy" rating and a $106.00 target price for the company. Oppenheimer began coverage on Monopar Therapeutics in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $77.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. BTIG Research upped their target price on Monopar Therapeutics from $87.00 to $104.00 and gave the company a "buy" rating in a research note on Thursday, September 25th. Finally, HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the company a "buy" rating in a research note on Monday.

Insider Activity at Monopar Therapeutics

In other news, CEO Chandler Robinson sold 16,800 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the chief executive officer directly owned 73,472 shares in the company, valued at $2,938,880. This represents a 18.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Tactic Pharma Llc sold 550,229 shares of the company's stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the sale, the insider owned 272,026 shares of the company's stock, valued at $17,303,573.86. This represents a 66.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 592,733 shares of company stock worth $36,700,227. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey acquired a new stake in Monopar Therapeutics during the 2nd quarter worth approximately $34,000. AlphaQuest LLC acquired a new stake in Monopar Therapeutics during the 1st quarter worth approximately $44,000. JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Monopar Therapeutics in the second quarter worth $80,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Monopar Therapeutics in the second quarter worth $104,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $81.67 on Wednesday. Monopar Therapeutics has a 1 year low of $4.50 and a 1 year high of $81.89. The company has a market capitalization of $503.90 million, a P/E ratio of -24.53 and a beta of 1.20. The business has a 50 day moving average price of $45.78 and a 200 day moving average price of $40.11.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. As a group, research analysts expect that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.